Thrive Health Solutions also faces a lawsuit from drugmaker Eli Lilly, for allegedly making false claims about FDA approval when selling compounded version of tirzepatide.

Hims & Hers Health, Inc. (NYSE:HIMS) is among the 13 Best Booming Stocks to Buy Now. On July 9, the digital health and ...

Blockbuster weight loss drugs like Ozempic, Wegovy and Mounjaro may slash the risk of a disorder affecting nearly 7million ...

For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide ...

Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared ...

Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older adults. A small study found that up to 40% of weight loss from semaglutide ...

Among patients receiving semaglutide for obesity management, the risk for muscle loss may be higher in older adults and women ...

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

New research finds that men taking a GLP-1 for their obesity or type 2 diabetes often experience a rise in testosterone ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

If you’re struggling with your body image this summer, there is still time to reach your image goals. Robert Andrews Laser & Medical Aesthetics is here to help you out this summer.